- AdventHealth Research Institute
Used after breast surgery, regional node irradiation (RNI) is generally a standard part of treatment for patients with pathologically positive axillary nodes and aims to reduce the risk of cancer recurrence by killing any remaining cancer cells in those nodes. However, with the increasing use and efficacy of neo-adjuvant chemotherapy, many patients who initially present with positive axillary lymph nodes become pathologically tumor free after neoadjuvant chemotherapy. The benefit of RNI in this population of patients was unclear.
The phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial explored that question. The results were recently published in the New England Journal of Medicine with Eleftherios “Terry” Mamounas, MD, medical director of the breast program and research activities at AdventHealth Cancer Institute, serving as lead author. The study found that patients with positive axillary lymph nodes who become pathologically tumor free after neoadjuvant chemotherapy have low rates of disease recurrence and do not receive a statistically significant or clinically meaningful benefit from RNI at 5 years, supporting a shift in treatment strategy.
Click below to read more.
Recent News
Clinical Trial Evidence on Diet and Type 1 Diabetes Outcomes
A new systematic review of clinical trials has found that no single dietary pattern consistently improves blood sugar control or weight management in youth and adults living with type 1 diabetes.
How Diet Shapes Gut Microbes and Energy Absorption
What we eat has a big impact on the bacteria living in our gut, which in turn affects how our bodies use energy—something that plays a major role in the development and treatment of obesity.
AdventHealth Neuroscience Institute Launches NIH-Funded THRIVE Trial
AdventHealth Neuroscience Institute has launched THRIVE, an NIH-funded clinical trial led by Lauren Oberlin, PhD, geriatric neuropsychologist and neuroscience researcher.
AdventHealth Tampa Enrolls First Patient in the Tectonic CAD IVL Trial
On September 19, 2025, AdventHealth Tampa successfully enrolled its first patient in the Tectonic CAD Intravascular Lithotripsy (IVL) Trial, led by Dr. Mahmaljy and his team.
MANIFEST US Study Presented as a Late-Breaking Clinical Trial at AHA
The cardiovascular team is excited to highlight the MANIFEST US study, which was presented on November 10th as a Late-Breaking Clinical Trial at the American Heart Association (AHA) Scientific...
Nourishing Your Gut: Dr. Karen Corbin on the Power of Fiber
Dr. Karen Corbin, associate investigator at the AdventHealth Translational Research Institute for Metabolism and Diabetes in Orlando, emphasizes the essential role of diet in maintaining a healthy gut...
Southeast Region – Redmond Campus: AdventHealth Recognized as Top Enroller Nationally for the CARVTOP-ICD Trial
AdventHealth Research Institute (AHRI) is proud to announce that the Southeast Region’s Redmond Campus has been recognized as the top enrolling site nationally for the CARVTOP-ICD trial.
Stiff Arteries Linked to Early Memory Decline: New Findings by Dr. Amani Norling
Amani Norling, PhD a post-doctoral fellow at the AdventHealth Neuroscience institute, has published a notable paper titled “Arterial stiffness moderates the link between NfL and cognition: The IGNITE...
First BrioVAD Implant Successfully Completed
On September 24, the Transplant team successfully implanted the first BrioVAD device at AdventHealth, a major milestone in the ongoing INNOVATE 2254936 Vidic trial.
Advancing T1D Science: New TRI Publications
Researchers at the AdventHealth Translational Research Institute continue to drive meaningful progress in Type 1 diabetes—work that is being recognized not just in Central Florida, but throughout the...
The T1D Daily Reset: Small Habits With Big Impact
As we head into 2026, many people living with Type 1 diabetes are looking for ways to reset their routines and start the year feeling more balanced and in control.
The Next Frontier: Preventing Type 1 Diabetes Before It Starts
Recent research led by AdventHealth’s Translational Research Institute and others reveals that Type 1 diabetes develops gradually and can now be detected early through blood tests, opening the door to...